<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acne vulgaris: Management of moderate to severe acne in adolescents and adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acne vulgaris: Management of moderate to severe acne in adolescents and adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acne vulgaris: Management of moderate to severe acne in adolescents and adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Emmy Graber, MD, MBA</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cindy Owen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1405871571"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acne vulgaris is a common cutaneous disorder that can cause discomfort, disfigurement, and negative psychosocial effects. Clinical presentations of acne vulgaris vary widely, ranging from minor skin involvement to extensive presentations. (See  <a class="medical medical_review" href="/z/d/html/39.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris", section on 'Clinical manifestations'</a>.)</p><p>Treatment options for acne vulgaris include topical, oral, and procedural therapies  (<a class="graphic graphic_table graphicRef55642" href="/z/d/graphic/55642.html" rel="external">table 1</a>). Although topical therapy is the mainstay of treatment for mild acne vulgaris  (<a class="graphic graphic_algorithm graphicRef130204" href="/z/d/graphic/130204.html" rel="external">algorithm 1</a>), patients with moderate to severe presentations may benefit from systemic therapy  (<a class="graphic graphic_algorithm graphicRef130260" href="/z/d/graphic/130260.html" rel="external">algorithm 2</a>).</p><p>The therapeutic approach to moderate to severe acne vulgaris will be reviewed here. General treatment principles and the management of mild acne vulgaris are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/42.html" rel="external">"Acne vulgaris: Overview of management"</a>.)</p><p></p><p>The management of acne vulgaris in infants, young children, and preadolescents is reviewed in detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/131570.html" rel="external">"Acne in infants, young children, and preadolescents"</a>.)</p><p></p><p>Other aspects of the manifestations, diagnosis, and management of acne vulgaris and acne scars are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/39.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13615.html" rel="external">"Postadolescent acne in women"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/37.html" rel="external">"Light-based, adjunctive, and other therapies for acne vulgaris"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/90260.html" rel="external">"Management of acne scars"</a>.)</p><p></p><p class="headingAnchor" id="H4073598194"><span class="h1">DEFINITION OF MODERATE TO SEVERE ACNE</span><span class="headingEndMark"> — </span>There is no universally accepted grading system for assessing severity. Examples of findings that may be considered supportive of moderate to severe involvement include one or more of the following  (<a class="graphic graphic_picture graphicRef98493 graphicRef98494 graphicRef57925 graphicRef55681" href="/z/d/graphic/98493.html" rel="external">picture 1A-D</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Visually prominent acne consisting of many comedones, inflamed papules, or pustules</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of large, inflamed papules or nodules (lesions &gt;5 mm in diameter)</p><p class="bulletIndent1"><span class="glyph">●</span>Involvement of multiple body areas </p><p class="bulletIndent1"><span class="glyph">●</span>Associated scarring </p><p></p><p>The clinician should also consider the psychologic burden of acne vulgaris in the assessment of severity. In some patients, acne that appears relatively mild causes significant psychologic distress, warranting a more aggressive therapeutic approach, similar to the approach for moderate to severe acne  (<a class="graphic graphic_algorithm graphicRef130260" href="/z/d/graphic/130260.html" rel="external">algorithm 2</a>).</p><p class="headingAnchor" id="H2037856433"><span class="h1">GENERAL APPROACH</span><span class="headingEndMark"> — </span>Topical and systemic therapies are the mainstays of treatment for moderate to severe acne vulgaris. Procedural interventions are primarily utilized as adjunctive therapies. (See  <a class="medical medical_review" href="/z/d/html/37.html" rel="external">"Light-based, adjunctive, and other therapies for acne vulgaris"</a>.)</p><p class="headingAnchor" id="H2503228875"><span class="h2">When to use systemic therapy</span><span class="headingEndMark"> — </span>Moderate to severe acne vulgaris is often treated systemically to optimize and simplify treatment. The primary systemic therapies for acne vulgaris include oral antibiotics (typically tetracyclines), hormonal therapies (oral contraceptives or <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>), and oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>  (<a class="graphic graphic_algorithm graphicRef130260" href="/z/d/graphic/130260.html" rel="external">algorithm 2</a>). With the exception of oral isotretinoin, systemic therapy is typically combined with topical therapy. (See <a class="local">'Use of topical therapy'</a> below.)</p><p>The clinical presentation and patient preference influence the decision to initiate systemic therapy. Clinical findings prompting systemic therapy include nodular lesions, extensive skin involvement, scarring, and psychologic disturbance related to acne. In the absence of such findings, an initial trial of topical therapy alone is a reasonable alternative; however, we typically discuss the option for systemic therapy with all patients with moderate to severe acne vulgaris. (See <a class="local">'Use of topical therapy'</a> below.)</p><p class="headingAnchor" id="H1240593136"><span class="h2">Selection of a systemic therapy</span><span class="headingEndMark"> — </span>Selection among the systemic treatments (oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, oral antibiotics, oral hormonal agents) involves consideration of patient-specific characteristics and the values and preferences of individual patients  (<a class="graphic graphic_algorithm graphicRef130260" href="/z/d/graphic/130260.html" rel="external">algorithm 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> — The types of lesions present and severity of acne vulgaris influence selection of therapy:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Types of lesions</strong> – The classic lesions of acne vulgaris include closed comedones, open comedones, and papulopustular or nodular lesions. (See  <a class="medical medical_review" href="/z/d/html/39.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris", section on 'Classic features'</a>.)</p><p></p><p class="bulletIndent2">Oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, oral contraceptives, and <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> are considered beneficial for all manifestations of acne vulgaris and, therefore, can be used as the primary systemic therapy for patients with exclusively comedonal, papulopustular, nodular, or mixed presentations. In contrast, oral antibiotics are primarily utilized for papulopustular or nodular manifestations. Although oral antibiotics may contribute to improvement in all lesion types, they are considered most effective for papulopustular and nodular lesions. (See <a class="local">'Oral antibiotics'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severity</strong> – Although oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, oral antibiotics, oral contraceptives, and <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> are all effective treatments, severe, extensive, nodular acne vulgaris warrants early consideration of oral isotretinoin therapy. Oral isotretinoin is considered the only medication that can permanently alter the natural course of acne vulgaris and has the potential to induce long-term remissions off therapy. (See <a class="local">'Oral isotretinoin'</a> below and <a class="local">'Acne fulminans'</a> below and <a class="local">'Acne conglobata'</a> below.)</p><p></p><p class="bulletIndent2">Use of oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> can also be appropriate for less severe presentations. Examples of scenarios in which early use of isotretinoin may be preferred include patients with acne-induced scarring or acne-related, psychosocial distress [<a href="#rid1">1</a>]. Moderate acne that has failed to respond to other treatments is also an appropriate indication for isotretinoin. Risk for multiple adverse effects, including teratogenicity, limit the initial use of oral isotretinoin for mild, uncomplicated acne vulgaris. (See  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sex and age</strong> – The option for systemic hormonal therapy (oral contraceptives, <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>) for acne vulgaris is limited to postmenarchal female patients.</p><p></p><p class="bulletIndent1">Special considerations for the treatment of children and adolescents are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/42.html" rel="external">"Acne vulgaris: Overview of management", section on 'Children'</a> and  <a class="medical medical_review" href="/z/d/html/131570.html" rel="external">"Acne in infants, young children, and preadolescents", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy and childbearing potential</strong> – Certain systemic therapies are not recommended during pregnancy. In particular, pregnant individuals should not receive oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, oral tetracyclines, oral contraceptives, or <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>.</p><p></p><p class="bulletIndent1">Oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> is a teratogenic drug that is contraindicated for pregnant individuals and individuals of childbearing potential who are not able or willing to adhere to highly effective measures to prevent pregnancy. In the United States, oral isotretinoin therapy requires participation in a Risk Evaluation and Mitigation Strategy (REMS) program. (See  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris"</a>.)</p><p></p><p class="bulletIndent1">Administration of tetracyclines to pregnant individuals is associated with risk for permanent discoloration of developing teeth. <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">Spironolactone</a> is associated with a theoretical risk for feminization of a male fetus. Oral contraceptives are indicated to prevent pregnancy and are contraindicated in pregnancy. (See <a class="local">'Tetracyclines'</a> below and <a class="local">'Oral contraceptives'</a> below and <a class="local">'Spironolactone'</a> below.)</p><p></p><p class="bulletIndent1">Alternative antibiotics may be helpful for pregnant individuals who require systemic therapy. (See  <a class="medical medical_review" href="/z/d/html/42.html" rel="external">"Acne vulgaris: Overview of management", section on 'Pregnant individuals'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for adverse effects</strong> – Systemic acne therapies are generally well tolerated. However, certain characteristics may increase risk for adverse effects, making therapies less favorable for individual patients. (See  <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use"</a> and  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris", section on 'Contraindications and precautions'</a> and <a class="local">'Spironolactone'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient values and preferences</strong> – Effective systemic therapies for acne vulgaris vary in respect to regimens, adverse effects profiles, and expected outcomes, contributing to an important role for patient preference in treatment selection. A comprehensive discussion with the patient regarding the treatment options is essential for identifying the ideal approach to therapy. For example, a female patient who prefers to avoid long-term oral therapy may prefer to avoid oral contraceptives or <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>.</p><p></p><p class="bulletIndent1">The discussion with the patient also provides the opportunity to address questions, concerns, and misconceptions regarding specific treatments. Given the high prevalence of acne vulgaris and the common use of acne therapies for other indications, patients often have some familiarity with the treatment options and may have pre-existing impressions of specific therapies.</p><p></p><p class="headingAnchor" id="H906488171"><span class="h2">Use of topical therapy</span><span class="headingEndMark"> — </span>With the exception of oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, which is typically given as monotherapy, combining topical and systemic therapy is generally advised for patients treated with oral antibiotics or hormonal therapy to optimize the response to therapy. </p><p>Patients who prefer to avoid systemic therapy are typically treated with multiple skin-directed therapies. Selection of treatment is focused on combating different aspects of the pathogenesis of acne vulgaris. Our minimum approach resembles the approach to topical therapy for mild acne vulgaris, with the inclusion of a retinoid and <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">benzoyl peroxide</a> for patients with papulopustular manifestations. We have a low threshold for the addition of other topical therapies with different mechanisms of action, such as topical antibiotics, topical <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, salicylic acid, and <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a>. Combination products can be helpful for simplifying the treatment regimen  (<a class="graphic graphic_table graphicRef56087" href="/z/d/graphic/56087.html" rel="external">table 2</a>). (See <a class="local">'Other agents'</a> below and  <a class="medical medical_review" href="/z/d/html/42.html" rel="external">"Acne vulgaris: Overview of management", section on 'Mild acne vulgaris'</a> and  <a class="medical medical_review" href="/z/d/html/39.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris", section on 'Pathogenesis'</a>.)</p><p>Patients may also benefit from the incorporation of procedural therapies, such as chemical peels or laser therapy. (See <a class="local">'Procedural therapy'</a> below and  <a class="medical medical_review" href="/z/d/html/37.html" rel="external">"Light-based, adjunctive, and other therapies for acne vulgaris", section on 'Adjunctive therapies'</a> and  <a class="medical medical_review" href="/z/d/html/37.html" rel="external">"Light-based, adjunctive, and other therapies for acne vulgaris", section on 'Light/laser therapies'</a>.)</p><p class="headingAnchor" id="H1312600026"><span class="h3">Topical retinoids</span><span class="headingEndMark"> — </span>Topical retinoids are effective for both comedonal and papulopustular manifestations of acne vulgaris and are considered a mainstay of acne therapy. We aim to incorporate a topical retinoid for all patients receiving systemic antibiotic or hormonal therapy. Topical retinoids also play a key role in maintaining treatment responses following the discontinuation of oral antibiotics or other therapies [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/42.html" rel="external">"Acne vulgaris: Overview of management", section on 'Topical retinoids'</a> and  <a class="medical medical_review" href="/z/d/html/42.html" rel="external">"Acne vulgaris: Overview of management", section on 'Maintenance of response'</a>.)</p><p class="headingAnchor" id="H2560808044"><span class="h3">Benzoyl peroxide</span><span class="headingEndMark"> — </span>Antibiotic therapy for acne vulgaris should be given in conjunction with topical <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">benzoyl peroxide</a> whenever feasible. Antibiotics may promote the appearance of antibiotic-resistant strains of <em>Cutibacterium</em> (formerly <em>Propionibacterium</em>)<em> acnes</em> when used alone. Combining antibiotic therapy with the use of benzoyl peroxide decreases the development of antibiotic resistance and improves treatment efficacy [<a href="#rid3">3-8</a>]. The antimicrobial effects of benzoyl peroxide may also be beneficial for patients who are not receiving antibiotic therapy. (See  <a class="medical medical_review" href="/z/d/html/42.html" rel="external">"Acne vulgaris: Overview of management", section on 'Benzoyl peroxide'</a>.)</p><p class="headingAnchor" id="H2183390539"><span class="h3">Other agents</span><span class="headingEndMark"> — </span>A variety of other topical agents (eg, topical antibiotics, topical <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, topical <a class="drug drug_general" data-topicid="129396" href="/z/d/drug information/129396.html" rel="external">clascoterone</a>, salicylic acid, and <a class="drug drug_general" data-topicid="9038" href="/z/d/drug information/9038.html" rel="external">azelaic acid</a>) may be beneficial for moderate to severe acne vulgaris. We primarily use these agents when topical retinoids and <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">benzoyl peroxide</a> are unavailable, poorly tolerated, or insufficiently effective. (See  <a class="medical medical_review" href="/z/d/html/42.html" rel="external">"Acne vulgaris: Overview of management", section on 'Resistant disease'</a>.)</p><p>Topical antibiotics are generally reserved for patients who are <strong>not </strong>simultaneously receiving oral antibiotics. Antibiotic resistance to topical antibiotics may limit the efficacy of these agents and has contributed to reduced use of topical <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> for acne vulgaris. (See  <a class="medical medical_review" href="/z/d/html/42.html" rel="external">"Acne vulgaris: Overview of management", section on 'Principles'</a> and  <a class="medical medical_review" href="/z/d/html/42.html" rel="external">"Acne vulgaris: Overview of management", section on 'Topical erythromycin'</a> and  <a class="medical medical_review" href="/z/d/html/42.html" rel="external">"Acne vulgaris: Overview of management", section on 'Topical clindamycin'</a>.)</p><p class="headingAnchor" id="H3189544520"><span class="h2">Procedural therapy</span><span class="headingEndMark"> — </span>Procedural interventions, such as intralesional corticosteroid injections, chemical peels, acne surgery, and light or laser therapies, are primarily utilized as adjunctive treatments. Adjunctive therapies for acne vulgaris are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/37.html" rel="external">"Light-based, adjunctive, and other therapies for acne vulgaris"</a>.)</p><p class="headingAnchor" id="H1564370188"><span class="h1">ORAL ISOTRETINOIN</span><span class="headingEndMark"> — </span>Oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> is a retinoid that counteracts acne vulgaris. It is the only acne medication that combats all four factors in acne pathogenesis (ie, sebum production, follicular hyperkeratinization, inflammation, and <em>C. acnes</em>). This includes inhibition of sebum secretion from sebaceous glands, thereby inhibiting proliferation of <em>C. acnes</em>, inhibition of comedogenesis through promotion of keratinocyte differentiation and normalization of epidermal desquamation, and intrinsic anti-inflammatory properties. (See  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris"</a> and  <a class="medical medical_review" href="/z/d/html/39.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H3510009329"><span class="h2">Appropriate use</span><span class="headingEndMark"> — </span>Oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> is well accepted as a treatment for severe, recalcitrant, nodular acne [<a href="#rid1">1</a>]. In clinical practice, it is also used for less severe acne that is resistant to other treatments or associated with scarring. The risk for adverse effects, including teratogenicity, inhibits the use of isotretinoin as a routine initial treatment for mild, uncomplicated acne. (See  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris"</a> and <a class="local">'Selection of a systemic therapy'</a> above.)</p><p class="headingAnchor" id="H4077910748"><span class="h2">Administration and efficacy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">Isotretinoin</a> is typically administered over a course of several months and is usually given as monotherapy. Dosing and administration of oral isotretinoin is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris", section on 'Initiation of therapy'</a>.)</p><p>Patients with severe acne vulgaris are at risk for isotretinoin-induced acne flares and may benefit from combination therapy with a systemic glucocorticoid at the start of treatment. (See  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris", section on 'Severe acne'</a> and <a class="local">'Acne fulminans'</a> below and <a class="local">'Acne conglobata'</a> below.)</p><p>Use of oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> is based upon reports of efficacy from randomized trials and observational studies [<a href="#rid9">9-21</a>]. However, high-quality, randomized trials to confirm efficacy and superiority over other therapies are lacking [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris"</a>.)</p><p class="headingAnchor" id="H971939816"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">Isotretinoin</a> is teratogenic and, therefore, contraindicated in pregnancy. Because of this risk, participation in a Risk Evaluation and Mitigation Strategy (REMS) program is required for isotretinoin therapy in the United States. (See  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris", section on 'iPLEDGE program'</a>.)</p><p>Examples of other adverse effects of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> include dry skin and mucous membranes, visual changes, hyperlipidemia, elevation of hepatic transaminase levels, and myalgias. Adverse effects of oral isotretinoin are reviewed in detail separately. (See  <a class="drug drug_general" href="/z/d/drug information/8582.html" rel="external">"Isotretinoin: Drug information"</a>.)</p><p class="headingAnchor" id="H2209063308"><span class="h1">ORAL ANTIBIOTICS</span><span class="headingEndMark"> — </span>Oral antibiotics improve inflammatory lesions of acne vulgaris by inhibiting the growth of <em>C. acnes</em> within the pilosebaceous unit. Benefit of oral antibiotics, particularly tetracyclines, is also thought to result from direct anti-inflammatory properties [<a href="#rid23">23</a>]. (See <a class="local">'Selection of a systemic therapy'</a> above.)</p><p class="headingAnchor" id="H1087954710"><span class="h2">Appropriate use</span><span class="headingEndMark"> — </span>A typical course of antibiotic therapy for acne vulgaris consists of continuous treatment for three months [<a href="#rid24">24</a>]. Selection of an appropriate agent and adherence to measures to reduce risk for antibiotic resistance are important considerations for antibiotic therapy. Although lessened use of antibiotics whenever feasible is advised as part of antibiotic stewardship [<a href="#rid25">25</a>], some patients with moderate to severe acne vulgaris are not candidates for other systemic therapies, necessitating the use of oral antibiotics (see  <a class="medical medical_review" href="/z/d/html/112487.html" rel="external">"Antimicrobial stewardship in outpatient settings"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic selection</strong> – Tetracyclines are the preferred oral antibiotics for acne vulgaris based upon efficacy and tolerability. Other antibiotics (macrolides, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, cephalosporins, and penicillins) are generally reserved for patients who fail or cannot tolerate tetracyclines [<a href="#rid1">1</a>]. However, we usually proceed to nonantibiotic therapies, such as oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, when patients fail to improve with tetracyclines. (See <a class="local">'Tetracyclines'</a> below and <a class="local">'Alternative antibiotics'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Measures to reduce antibiotic resistance</strong> – Appropriate use of oral antibiotics for acne vulgaris involves implementation of measures to reduce risk for the development of antibiotic resistance. (See  <a class="medical medical_review" href="/z/d/html/112487.html" rel="external">"Antimicrobial stewardship in outpatient settings"</a>.)</p><p></p><p class="bulletIndent1">Key measures include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Limiting duration of treatment</strong> – Oral antibiotics should be prescribed for the shortest possible period of time. Ideally, treatment is limited to continuous therapy for three to four months, with simultaneous use of a topical retinoid to facilitate discontinuation of the antibiotic [<a href="#rid1">1</a>]. Select patients who require longer courses should be followed closely to ensure that antibiotic therapy is given for the shortest duration necessary [<a href="#rid1">1</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Incorporating use of </strong><strong>benzoyl peroxide</strong> – <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">Benzoyl peroxide</a> should be included in the treatment regimen. Antibiotic therapy can promote the appearance of antibiotic-resistant strains <em>of C. acnes</em>; concomitant use of benzoyl peroxide has an inhibitory effect on the development of antibiotic resistance. (See <a class="local">'Benzoyl peroxide'</a> above and  <a class="medical medical_review" href="/z/d/html/42.html" rel="external">"Acne vulgaris: Overview of management", section on 'Benzoyl peroxide'</a>.)</p><p></p><p class="bulletIndent1">Antibiotic resistance is increasing in patients with acne vulgaris [<a href="#rid26">26</a>]. One report suggests that the incidence of <em>C. acnes</em> antibiotic resistance increased from 20 percent in 1978 to 62 percent in 1996 [<a href="#rid27">27</a>]. Factors that contribute to this increasing incidence include the widespread use of oral antibiotics and the practice of rotating antibiotics. Resistance is most commonly reported with <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a>. Resistance to <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> is rare but may be emerging in the United States [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1">The rise of <em>C. acnes</em> antibiotic resistance is a concern for acne management; there is some evidence that the presence of resistant organisms can reduce treatment efficacy [<a href="#rid29">29</a>]. There is also concern that long-term antibiotic therapy affects other host bacterial flora, although the clinical impact of this is unclear. In one cross-sectional study (n = 107), patients taking oral tetracyclines (<a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, or <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>) or topical antibiotics for at least three months had a threefold increase in the prevalence of <em>Streptococcus pyogenes</em> in the oropharynx compared with those who were not on antibiotic therapy (33 versus 10 percent) [<a href="#rid30">30</a>]. However, the number of patients reporting upper respiratory tract illness or symptoms was not different in the two groups.</p><p></p><p class="bulletIndent1">Other studies have found an increased rate of upper respiratory infections in acne patients treated with oral antibiotic therapy. A more than threefold increase in pharyngitis was reported in a prospective, cohort study and a cross-sectional study, and a large, retrospective study (n = 118,496) found a twofold greater risk for upper respiratory infection among acne patients treated with either topical or oral antibiotics [<a href="#rid31">31,32</a>]. In the prospective study, which consisted of 36 university students with acne who received oral antibiotic therapy and 543 students with or without acne who were not treated with oral antibiotics, more students in the antibiotic therapy group reported visits to a health care provider for pharyngitis (11 versus 3 percent; adjusted odds ratio [OR] 4.34, 95% CI 1.51-12.47). In contrast to the cross-sectional study described above, an effect of antibiotic use on group A <em>Streptococcus</em> colonization was not detected. Further prospective studies are necessary to evaluate the effect of antibiotic therapy on upper respiratory tract infections.</p><p></p><p class="bulletIndent1">There are also data that suggest an association between systemic antibiotic therapy, especially broad spectrum antibiotic therapy, and increased risk for inflammatory bowel disease [<a href="#rid33">33,34</a>]. (See  <a class="medical medical_review" href="/z/d/html/4066.html" rel="external">"Definitions, epidemiology, and risk factors for inflammatory bowel disease", section on 'Antibiotics'</a> and  <a class="medical medical_review" href="/z/d/html/4077.html" rel="external">"Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease", section on 'Role of microbes'</a>.)</p><p></p><p class="headingAnchor" id="H1011651184"><span class="h2">Tetracyclines</span><span class="headingEndMark"> — </span>Multiple studies have shown tetracyclines effective for acne vulgaris [<a href="#rid35">35</a>]. Preferred tetracyclines for acne vulgaris therapy in the United States include <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, and <a class="drug drug_general" data-topicid="119255" href="/z/d/drug information/119255.html" rel="external">sarecycline</a>. Doxycycline and minocycline have replaced <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> and <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> as the most frequently used oral antibiotics for acne therapy by dermatologists in the United States, both due to better tolerability and the presence of higher rates of <em>C. acnes</em> resistance to erythromycin and tetracycline [<a href="#rid4">4,36</a>]. In addition, availability of tetracycline is limited in the United States.</p><p>Tetracyclines do not inhibit the efficacy of oral contraceptive pills for contraception (see  <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Drug interactions'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Doxycycline</strong><strong> </strong>– Typical dosing for adolescents and adults for <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>50 or 100 mg twice daily or 100 mg once daily [<a href="#rid1">1,35,37</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Delayed release: loading dose of 100 mg every 12 hours for one day, then as 100 mg once daily</p><p class="bulletIndent2"><span class="glyph">•</span>Subantimicrobial dosing: 40 mg once daily (delayed release) or 20 mg twice daily [<a href="#rid38">38-40</a>]</p><p></p><p class="bulletIndent1">We typically treat with 100 mg twice daily.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">Doxycycline</a> and other tetracyclines should<strong> not </strong>be given to children up to the age of eight years or to pregnant individuals due to the potential for discoloration of developing permanent teeth with long-term treatment. In addition, doxycycline can cause gastrointestinal distress, esophagitis, esophageal ulceration, or idiopathic intracranial hypertension (pseudotumor cerebri). Administration with food can be helpful for reducing symptoms of gastrointestinal distress. Photosensitivity may also occur, and patients should be encouraged to engage in sun-protective behaviors. Additional adverse effects are reviewed separately. (See  <a class="drug drug_general" href="/z/d/drug information/9393.html" rel="external">"Doxycycline: Drug information"</a>.)</p><p></p><p class="bulletIndent1">Several randomized trials have evaluated the efficacy of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> for acne vulgaris. In a cross-over trial in which 62 patients with predominantly inflammatory acne were treated with either doxycycline (50 mg twice daily) or placebo for four weeks, discontinued treatment for four weeks, and then switched treatment for four weeks, statistically significant reductions in inflammatory lesion counts occurred after treatment with doxycycline but not after treatment with placebo [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1">Subantimicrobial dosing of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (40 mg per day) may also improve acne vulgaris [<a href="#rid38">38-40</a>]. Subantimicrobial doses aim to maintain anti-inflammatory properties but eliminate antibacterial action, reducing the potential for inducing antibacterial resistance. In a 16-week trial in which 662 patients with moderate to severe acne vulgaris were randomly assigned to a modified-release form of doxycycline 40 mg, doxycycline 100 mg, or placebo once daily, modified-release doxycycline 40 mg was associated with greater reductions in the inflammatory lesion count than doxycycline 100 mg and placebo [<a href="#rid40">40</a>]. In addition, adverse effects were less frequent with modified-release doxycycline 40 mg than doxycycline 100 mg.</p><p></p><p class="bulletIndent1">Subantimicrobial dosing of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (20 mg twice daily) was also more effective than placebo for moderate to severe acne vulgaris in a randomized trial that included 51 patients with moderate facial acne [<a href="#rid38">38</a>]. In another randomized trial (n = 100), patients with moderate facial acne treated with either 20 mg or 100 mg of doxycycline twice daily exhibited numerically similar reductions in inflammatory lesions [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minocycline</strong> – <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">Minocycline</a> is not typically used as first-line therapy due to greater toxicity concerns compared with other tetracyclines [<a href="#rid42">42,43</a>]. Typical dosing for minocycline for adolescents and adults:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>50 or 100 mg daily or twice daily [<a href="#rid1">1,35,37,44</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Extended release: 1 mg/kg per day (maximum 135 mg per day) [<a href="#rid45">45-47</a>]</p><p></p><p class="bulletIndent1">We typically treat with 100 mg twice daily. </p><p></p><p class="bulletIndent1">In the past, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> was widely considered more effective than <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> and <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> [<a href="#rid4">4,48,49</a>]. This was based on a theory, as minocycline is lipophilic and could thereby better penetrate into the pilosebaceous unit. However, a 2012 systematic review of randomized trials did not find sufficient evidence to support superiority of minocycline [<a href="#rid44">44</a>]. </p><p></p><p class="bulletIndent1">Similar to <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> should not be given to children up to the age of eight years or pregnant individuals. Minocycline is the only <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> member to cross the blood-brain barrier and may impart vestibular side effects, such as headache, dizziness, and vertigo. In addition, minocycline may impart a serum sickness reaction that typically occurs days after initiation, skin discoloration  (<a class="graphic graphic_picture graphicRef98518 graphicRef79772" href="/z/d/graphic/98518.html" rel="external">picture 2A-B</a>), idiopathic intracranial hypertension, a lupus-like syndrome [<a href="#rid50">50-53</a>], and photosensitivity. Minocycline is less photosensitizing than doxycycline and tetracycline. Additional adverse effects are reviewed separately. (See  <a class="drug drug_general" href="/z/d/drug information/122965.html" rel="external">"Minocycline (systemic): Drug information"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sarecycline</strong> – <a class="drug drug_general" data-topicid="119255" href="/z/d/drug information/119255.html" rel="external">Sarecycline</a> is a <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> with a narrower spectrum of antibiotic activity [<a href="#rid54">54,55</a>]. Typical dosing:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Once-daily, weight-based dosing: 60 mg for patients weighing 33 to 54 kg, 100 mg for patients weighing 55 to 84 kg, 150 mg for patients weighing 85 to 136 kg</p><p></p><p class="bulletIndent1">An advantage of the narrower spectrum of antibiotic activity is a lower propensity to promote the development of <em>C. acnes </em>resistance and the potential for less disruption of the gut microbiome [<a href="#rid55">55</a>]. Other tetracyclines (<a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>) have a broader spectrum of antibiotic activity, including greater activity against gram-negative bacilli in the normal human intestinal microbiome [<a href="#rid56">56</a>]. (See <a class="local">'Appropriate use'</a> above.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="119255" href="/z/d/drug information/119255.html" rel="external">Sarecycline</a> demonstrated efficacy for moderate to severe acne vulgaris in two placebo-controlled, phase 3, randomized trials (n = 968 and n = 1034) [<a href="#rid55">55</a>]. Rates of treatment success (investigator assessment of clear or almost clear and at least a two-point improvement on a five-point grading scale) for facial acne vulgaris at week 12 were 22 and 23 percent in the sarecycline groups compared with 11 and 15 percent in the placebo groups, respectively. Treatment success rates (at least a two-point improvement in the five-point grading scale) for back and chest acne were also greater for sarecycline than for placebo. The efficacy of sarecycline has not been compared with other tetracyclines.</p><p></p><p class="bulletIndent1">As with other tetracyclines, <a class="drug drug_general" data-topicid="119255" href="/z/d/drug information/119255.html" rel="external">sarecycline</a> should not be given to children up to the age of eight years or pregnant individuals. Nausea is a potential adverse effect of sarecycline. (See  <a class="drug drug_general" href="/z/d/drug information/119255.html" rel="external">"Sarecycline: Drug information"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tetracycline</strong> – Since 2011, availability of <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> has been limited in the United States. Typical dosing for adolescents and adults:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>250 to 500 mg twice daily </p><p></p><p class="bulletIndent1">Randomized trials support the efficacy of <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> for acne vulgaris [<a href="#rid57">57,58</a>]. In an eight-week trial that randomly assigned 305 patients with moderate to severe acne vulgaris to tetracycline (250 mg twice daily), <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> 1% solution twice daily, or placebo, both tetracycline and clindamycin were more effective for reducing papule and pustule counts than placebo [<a href="#rid57">57</a>]. In addition, a trial in which 200 patients with moderate to moderately severe acne vulgaris were treated with either tetracycline (1 g per day for four weeks, then 500 mg per day for eight weeks) or <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> base (1 g for four weeks, then 333 mg per day for eight weeks) found the treatments similarly effective for reducing acne severity [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1">Absorption of <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> is inhibited by food, dairy products, antacids, and iron; it must be taken on an empty stomach. Tetracycline should be taken at least one hour prior to a meal or two hours after eating.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">Tetracycline</a> should not be given to children up to the age of eight years or pregnant individuals. Examples of adverse effects include gastrointestinal distress, photosensitivity, and idiopathic intracranial hypertension. (See  <a class="drug drug_general" href="/z/d/drug information/9986.html" rel="external">"Tetracycline: Drug information"</a>.)</p><p></p><p class="headingAnchor" id="H1948112760"><span class="h2">Alternative antibiotics</span><span class="headingEndMark"> — </span>Antibiotics other than tetracyclines are generally reserved for patients who cannot tolerate or who fail to respond to tetracyclines and who are not candidates for other systemic therapies, such as <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>, or oral contraceptives. We use alternative antibiotics infrequently.</p><p class="headingAnchor" id="H4239252032"><span class="h3">Macrolides</span><span class="headingEndMark"> — </span>The macrolides most often used for acne vulgaris are <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> and <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a>:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Azithromycin</strong> – A wide variety of regimens have been utilized in studies that support <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> efficacy [<a href="#rid58">58-63</a>]. A 2018 meta-analysis of randomized trials that compared azithromycin pulse therapy (500 mg one to three times per week or four times monthly) with <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg once or twice daily) found similar efficacy for moderate to severe acne vulgaris [<a href="#rid59">59</a>]. </p><p></p><p class="bulletIndent1">Concern for routine use of <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> for acne vulgaris is related to the rising incidence of antibiotic resistance to this drug. Azithromycin is often used as a first-line agent for the treatment of respiratory infections and is also prescribed as an alternative drug for the treatment of other gram-positive cocci infections in patients allergic to beta-lactam antibiotics. The risk of increasing the prevalence of antibiotic resistance makes azithromycin a less favorable choice for routine acne therapy. (See  <a class="medical medical_review" href="/z/d/html/474.html" rel="external">"Azithromycin and clarithromycin", section on 'Resistance'</a> and  <a class="medical medical_review" href="/z/d/html/7033.html" rel="external">"Resistance of <i>Streptococcus pneumoniae</i> to the macrolides, azalides, and lincosamides"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythromycin</strong> – Typical dosing for <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> for adolescents and adults is 500 mg twice daily. A disadvantage is the common occurrence of the development of <em>C. acnes</em> resistance to erythromycin, resulting in treatment failure [<a href="#rid64">64</a>]. In addition, many patients experience intolerable gastrointestinal side effects. </p><p></p><p class="bulletIndent1">Data to support efficacy of oral <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> are limited. A trial in which 200 patients with moderate to severe acne vulgaris were randomly assigned to oral erythromycin (1 g per day for four weeks, then 333 mg per day for eight weeks) or oral <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> (1 g/day for four weeks then 500 mg per day for eight weeks) found similar benefit for reducing acne severity [<a href="#rid58">58</a>]. </p><p></p><p class="headingAnchor" id="H4041134458"><span class="h3">Other antibiotics</span><span class="headingEndMark"> — </span>Routine use of antibiotics other than tetracyclines is discouraged [<a href="#rid1">1</a>]. Other antibiotic therapies that may be effective include <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (160 mg/800 mg once to twice daily for adults) and <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">cephalexin</a> (500 mg twice daily for adults) [<a href="#rid65">65</a>]. Data to support efficacy of these therapies are limited.</p><p class="headingAnchor" id="H4133876868"><span class="h1">ORAL HORMONAL THERAPIES</span><span class="headingEndMark"> — </span>Hormonal therapy with oral contraceptives and/or <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> is an option for female patients. The goal of hormonal therapy is to inhibit acne through reducing androgen action on cutaneous pilosebaceous units. (See  <a class="medical medical_review" href="/z/d/html/39.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris", section on 'Sebaceous glands and the role of androgens'</a>.)</p><p>Androgens contribute to acne vulgaris through the promotion of sebum production by sebaceous glands in the skin [<a href="#rid66">66</a>]. The increase in sebum production contributes to the accumulation of sebum and keratinous material in pilosebaceous follicles. This leads to partial obstruction of the follicle, resulting in the formation of comedones, the primary lesions of acne  (<a class="graphic graphic_picture graphicRef80536 graphicRef62816" href="/z/d/graphic/80536.html" rel="external">picture 3A-B</a>). Sebum also provides a growth medium for <em>C. acnes</em>, a bacterium that resides in pilosebaceous follicles and contributes to the inflammatory response in acne vulgaris  (<a class="graphic graphic_picture graphicRef70809" href="/z/d/graphic/70809.html" rel="external">picture 4</a>) [<a href="#rid67">67</a>]. (See  <a class="medical medical_review" href="/z/d/html/39.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H3096418988"><span class="h2">Appropriate use</span><span class="headingEndMark"> — </span>Postmenarchal females with moderate to severe acne vulgaris are the primary candidates for hormonal therapy. Both women with acne related to hyperandrogenism and women with acne and normal serum androgen levels can benefit from hormonal treatment [<a href="#rid1">1</a>]. </p><p>Women with milder acne who choose oral contraceptives for the purpose of pregnancy prevention can also experience the ancillary benefit of improvement in acne vulgaris. However, these patients can often be managed successfully with topical therapy. (See  <a class="medical medical_review" href="/z/d/html/42.html" rel="external">"Acne vulgaris: Overview of management", section on 'Mild acne vulgaris'</a>.)</p><p>Selection between oral contraceptives and <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> involves consideration of patient preferences and risk factors for adverse effects. Oral contraceptive treatment is often our initial choice for hormonal therapy for patients who also desire continuous contraception or who have other symptoms that may benefit from oral contraceptive therapy [<a href="#rid68">68</a>]. We tend to select spironolactone for patients who have other reliable methods of preventing pregnancy and who prefer to avoid oral contraceptive therapy or have contraindications to oral contraceptive therapy.</p><p><a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">Spironolactone</a> and oral contraceptives may also be given simultaneously. In the clinical setting, this is often done in an attempt to augment the response to therapy [<a href="#rid69">69</a>]. Combination therapy also prevents the spironolactone-induced menstrual irregularity that occurs in a subset of patients. </p><p>In general, hormonal therapy should be initiated with the intent of continuing treatment long-term to maintain improvement. Initial improvement is often delayed; at least three to six months of therapy is required for evaluation of efficacy.</p><p>Patients should be screened for risk factors for adverse effects prior to the start of hormonal therapy. (See  <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Candidates'</a> and <a class="local">'Spironolactone'</a> below.)</p><p class="headingAnchor" id="H2072466303"><span class="h2">Oral contraceptives</span><span class="headingEndMark"> — </span>Combined oral contraceptives containing both estrogen and progestin are effective therapies for acne vulgaris in female patients. Oral contraceptives containing estrogen and progestin may reduce androgen action via a variety of mechanisms.</p><p>The inhibitory effect of estrogens on acne is thought to be related to estrogen-mediated suppression of sebum production. However, the mechanism through which this occurs is not completely understood. Proposed mechanisms include estrogen-mediated opposition of androgens within the sebaceous gland, inhibition of gonadal androgen production through a negative feedback loop on gonadotrophin release, increases in sex hormone-binding globulin (which reduces the bioavailability of androgens), and effects on regulation of genes involved in sebaceous gland growth or lipid production [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">"Management of hirsutism in premenopausal women", section on 'Mechanisms of action in hyperandrogenism/hirsutism'</a>.)</p><p>Although most progestins in oral contraceptives have androgenic properties, all low-dose combination oral contraceptives are estrogen dominant and have an overall antiandrogenic effect [<a href="#rid68">68,70,71</a>]. Some progestins (eg, <a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">drospirenone</a>, <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">cyproterone acetate</a>, chlormadinone acetate, and <a class="drug drug_general" data-topicid="17068" href="/z/d/drug information/17068.html" rel="external">dienogest</a>) have antiandrogenic properties [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Hormone components'</a>.)</p><p>Progestin-only contraceptives, including low-dose oral pills that contain androgenic progestins (eg, <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> or desogestrel), are <strong>not</strong> effective and may exacerbate acne vulgaris [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">"Contraception: Progestin-only pills (POPs)"</a>.)</p><p class="headingAnchor" id="H2312594209"><span class="h3">Administration and efficacy</span><span class="headingEndMark"> — </span>Treatment regimens for oral contraceptive therapy for acne vulgaris are identical to regimens used for contraception. Only three oral contraceptives have been approved by the US Food and Drug Administration (FDA) for treatment of acne. These include ethinyl estradiol 20/30/35 mcg/<a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> 1 mg, ethinyl estradiol 35 mcg/norgestimate 180/215/250 mcg, and ethinyl estradiol 20 mcg/<a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">drospirenone</a> 3 mg.</p><p>A systematic review of randomized trials supported the efficacy of oral contraceptives over placebo [<a href="#rid68">68</a>]. However, efficacy differences between combined oral contraceptives with varying progestins are less clear. While newer, third-generation progestins (eg, norgestimate, desogestrel, and gestodene) are considered to be less androgenic than their earlier-generation precursors (eg, <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a>, <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a>), data are inadequate to conclude that third-generation agents offer superior efficacy for acne vulgaris [<a href="#rid68">68</a>] (see  <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Progestin'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination oral contraceptives with antiandrogenic progestins</strong> – Oral contraceptives with antiandrogenic progestins are a subclass of combination oral contraceptives. These include agents that contain <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">cyproterone acetate</a>, chlormadinone acetate, <a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">drospirenone</a>, or <a class="drug drug_general" data-topicid="17068" href="/z/d/drug information/17068.html" rel="external">dienogest</a> plus an estrogen [<a href="#rid74">74-76</a>]. Oral contraceptives containing cyproterone acetate or chlormadinone acetate are not available in the United States. Ethinyl estradiol 30 mcg/drospirenone 3 mg and ethinyl estradiol 20 mcg/drospirenone 3 mg are the two drospirenone-containing oral contraceptives that are prescribed in the United States.</p><p></p><p class="bulletIndent1">Examples of studies that support the efficacy of these agents include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A pooled analysis of two placebo-controlled, randomized trials with a total of 893 females with moderate facial acne found that patients treated with ethinyl estradiol 20 mcg/<a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">drospirenone</a> 3 mg for six cycles were more likely to attain clear or almost clear skin than patients treated with placebo (odds ratio [OR] 3.41, 95% CI 2.15-5.43) and had greater mean reductions in acne lesion counts [<a href="#rid77">77</a>]. In one trial, total lesion counts were reduced 46.3 percent for the combination oral contraceptive group and 30.6 percent for the placebo group [<a href="#rid78">78</a>]. Beneficial effects were observed by the third cycle.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An oral contraceptive containing ethinyl estradiol 30 mcg/<a class="drug drug_general" data-topicid="17068" href="/z/d/drug information/17068.html" rel="external">dienogest</a> 2 mg was superior to placebo in a large, randomized trial; total lesion counts were reduced by 55 versus 39 percent [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A randomized trial (n = 40) in which a topical form of <a class="drug drug_general" data-topicid="9295" href="/z/d/drug information/9295.html" rel="external">cyproterone acetate</a> was compared with oral ethinyl estradiol 35 mcg/cyproterone acetate 2 mg and placebo found that the oral agent was superior to placebo for reduction of the acne severity grade and lesion counts [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1">Although the results of a few randomized trials have suggested slightly greater benefit of ethinyl estradiol 30 mcg/<a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">drospirenone</a> 3 mg over ethinyl estradiol 35 mcg/norgestimate 0.18/0.125/0.25 mg [<a href="#rid80">80</a>] and for cyproterone acetate- or chlormadinone acetate-containing oral contraceptives over levonorgestrel-containing agents [<a href="#rid81">81-83</a>], additional high-quality trials are necessary to confirm these results. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comparison with oral antibiotic therapy</strong> – Few studies have directly compared the efficacy of oral contraceptive and oral antibiotic therapy [<a href="#rid84">84,85</a>], contributing to uncertainty regarding the relative efficacy of the two treatments. </p><p></p><p class="bulletIndent1">The results of the first meta-analysis to compare the efficacy of oral contraceptive therapy and oral antibiotic therapy suggest similar efficacy for the treatment of acne [<a href="#rid86">86</a>]. The meta-analysis included randomized trials that contained at least one investigational arm that consisted of oral antibiotic or oral contraceptive therapy and assessed efficacy for acne after three and/or six months of treatment. Analysis of the data after six months of treatment revealed that mean percent reductions in acne lesions after oral antibiotic treatment and oral contraceptive therapy were similar and superior to placebo (53, 55, and 25 percent, respectively). However, antibiotic therapy appeared to induce a more rapid response than oral contraceptive treatment. The mean percent reduction in acne lesions was significantly greater for oral antibiotics than oral contraceptives at the three-month time point (48 versus 37 percent, respectively).</p><p></p><p class="bulletIndent1">The findings of this study suggest similar efficacy of oral contraceptives and oral antibiotics and support the status of oral contraceptives as effective therapies for acne. Limitations of the meta-analysis included wide variation in treatment protocols and patient population (eg, trials of antibiotic therapy included both men and women, while oral contraceptive trials were limited to women). The performance of head-to-head trials would help to clarify the comparative efficacy of these treatments.</p><p></p><p class="headingAnchor" id="H3206895857"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>The risks and benefits of oral contraceptives should be discussed with all patients prior to the initiation of therapy. Thromboembolism is a potential serious adverse effect of oral contraceptive use, and treatment should be avoided in patients with underlying thrombophilic disorders or a history of a venous thromboembolic event [<a href="#rid87">87,88</a>]. Characteristics that inhibit the use of oral contraceptives are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Candidates'</a>.)</p><p><a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">Drospirenone</a> has a potassium-sparing, diuretic effect similar to <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>. Considerations for monitoring for hyperkalemia in patients treated with drospirenone-containing oral contraceptives are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Progestin'</a>.)</p><p>Package labeling for drospirenone-containing oral contraceptives advises against use in patients with renal impairment or adrenal insufficiency [<a href="#rid89">89</a>]. </p><p>In some cases, patients may be treated with oral contraceptives and oral antibiotics simultaneously. There is no definitive evidence that oral antibiotics, with the exception of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, reduce oral contraceptive effectiveness for pregnancy prevention [<a href="#rid90">90</a>]. The use of antibiotics other than rifampin does not warrant an additional form of pregnancy protection. (See  <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Drug interactions'</a>.)</p><p>Additional guidelines for the use of oral contraceptives are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use"</a> and  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns"</a>.)</p><p class="headingAnchor" id="H1915349456"><span class="h2">Spironolactone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">Spironolactone</a> is an oral antiandrogen that blocks androgen receptors and inhibits androgen biosynthesis [<a href="#rid66">66</a>]. The drug decreases 17-beta-hydroxysteroid dehydrogenase, therefore halting the conversion of androstenedione to testosterone [<a href="#rid91">91</a>]. Spironolactone may also inhibit 5-alpha-reductase, thereby preventing the conversion of testosterone to dihydrotestosterone (DHT). Additionally, spironolactone may increase steroid-hormone binding globulin [<a href="#rid92">92</a>]. Together, these mechanisms of action result in a 30 to 50 percent reduction in sebum excretion [<a href="#rid93">93</a>].</p><p class="headingAnchor" id="H2337026738"><span class="h3">Administration and efficacy</span><span class="headingEndMark"> — </span>Although the authors of a 2009 systematic review of randomized trials found insufficient evidence to confirm the efficacy of <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> for women with acne [<a href="#rid94">94</a>], multiple studies have reported treatment benefit [<a href="#rid69">69,95-104</a>].</p><p>We typically utilize doses of 50 to 100 mg per day (given in a single dose or in two divided doses) [<a href="#rid105">105</a>]. Initiating treatment with total doses of 25 or 50 mg per day, with subsequent dose escalation according to patient tolerance and response, may help to minimize side effects [<a href="#rid73">73</a>].</p><p>The largest studies assessing <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> therapy for acne vulgaris are retrospective analyses [<a href="#rid100">100,101</a>]. In a retrospective study of 395 patients with acne vulgaris (aged ≥21 years) treated with spironolactone (25 to 200 mg per day, median dose 100 mg per day, median treatment duration 13 months), 261 (66 percent) had an estimate of ≥90 percent improvement, 75 (19 percent) had 51 to 89 percent improvement, 25 (6 percent) had ≤50 percent improvement, and 34 (9 percent) had no evidence of response [<a href="#rid101">101</a>]. The median times to initial and maximal response were three and five months, respectively. Most patients (83 percent) received no other systemic acne therapies simultaneously other than oral contraceptive pills started more than six months prior to spironolactone. Adverse effects occurred in 10 percent of patients, with dizziness, irregular menstrual bleeding, and fatigue most common. </p><p>A similar retrospective study of 80 younger patients (ages 14 to 20 years) treated with <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> (25 to 200 mg per day, median dose 100 mg per day, median treatment duration seven months) for acne vulgaris at the same institution also supported benefit of spironolactone [<a href="#rid69">69</a>]. The study found ≥90 percent improvement in 18 patients (23 percent), 51 to 89 percent improvement in 29 patients (36 percent), ≤50 percent improvement in 17 patients (21 percent), and no response in 16 patients (20 percent).</p><p>Although <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> has been prescribed in doses of up to 200 mg per day for acne vulgaris and has demonstrated efficacy at this dose in a small, randomized trial [<a href="#rid69">69,95-97,101,106</a>], lower doses may still be effective and may reduce the risk for adverse effects [<a href="#rid98">98,107,108</a>]. In a randomized trial in which patients with moderate acne vulgaris received daily <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">benzoyl peroxide</a> plus spironolactone 50 mg, spironolactone 25 mg, or placebo, benzoyl peroxide plus spironolactone 50 mg was more effective than benzoyl peroxide plus placebo [<a href="#rid104">104</a>]. Moreover, a retrospective analysis found that responses to 50 to 100 mg per day of spironolactone were similar to previously reported responses to doses of 150 to 200 mg per day [<a href="#rid107">107</a>].</p><p class="headingAnchor" id="H2731027803"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>Side effects of <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> include menstrual irregularities, breast tenderness, minor gastrointestinal symptoms (anorexia, nausea, vomiting, and diarrhea), hyperkalemia, orthostatic hypotension, and central nervous system symptoms (headaches, dizziness, and fatigue). Side effects (excluding central nervous system symptoms) are less frequent at lower doses (≤100 mg per day) [<a href="#rid107">107</a>]. Side effects such as menstrual irregularities and breast tenderness can be counteracted by concomitant use of an oral contraceptive:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperkalemia</strong> – <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">Spironolactone</a> is a potassium-sparing diuretic, and hyperkalemia is a potentially serious adverse effect when given at high doses or to patients with renal insufficiency or severe heart failure [<a href="#rid109">109,110</a>]. However, there does not appear to be a significant risk for hyperkalemia in young, healthy women given spironolactone in doses typically used for acne [<a href="#rid106">106,107,111,112</a>]. Given that the risk of hyperkalemia is low, we do not monitor serum potassium levels in healthy, young women under the age of 45 years receiving spironolactone therapy for acne.</p><p></p><p class="bulletIndent1">However, the patient's comorbidities and medication history must be considered. Periodic laboratory monitoring of serum potassium is appropriate in women with multiple medical problems, cardiac disease, or renal disease and women who are taking medications that may increase risk for hyperkalemia [<a href="#rid66">66</a>]. In these patients, potassium levels can be checked at baseline, during therapy, and after dose increases [<a href="#rid1">1</a>]. Monitoring of serum potassium may also be beneficial for healthy women over the age of 45; we suggest periodic monitoring in this population:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The largest study of the risk for spironolactone-induced hyperkalemia in acne patients is a retrospective analysis of women (ages 18 to 45 years) prescribed <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> for acne or an endocrine disorder with acne as a secondary feature [<a href="#rid112">112</a>]. The rate of hyperkalemia in 1802 measurements from 974 women during treatment with spironolactone was 0.72 percent, and the baseline rate of hyperkalemia in 4209 measurements from 1165 women taking or not taking spironolactone was 0.76 percent. There were no serious elevations of potassium in the group taking spironolactone; all the elevations were mild or moderate. Of note, patients with heart failure or renal disease and patients receiving medications that affect the renin-angiotensin-aldosterone system were excluded. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A study that compared the rate of incident hyperkalemia during <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> therapy among 112 women aged 18 to 45 years and 12 women aged 46 to 65 years through the analysis of data in a medical record data repository supports a higher likelihood of hyperkalemia in older women (incident hyperkalemia in 0.01 and 17 percent of women, respectively) [<a href="#rid113">113</a>]. Included women had assessments of serum potassium at baseline (or within one year prior to the start of spironolactone) and within one year after the start of spironolactone. Women with hypertension, renal failure, or diabetes mellitus were excluded. </p><p></p><p class="bulletIndent1">The oral contraceptive progestin <a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">drospirenone</a> also possesses potassium-sparing, diuretic properties; 3 mg of drospirenone is equivalent to approximately 25 mg of <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> [<a href="#rid111">111</a>]. Although hyperkalemia was not demonstrated in one small, prospective study of patients concurrently taking oral contraceptives with drospirenone and 100 mg per day of spironolactone [<a href="#rid114">114</a>], further larger studies are needed to fully elucidate the risk of hyperkalemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignancy</strong> – There is a theoretical concern for increased risk for breast cancer based upon <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>'s estrogenic effects. However, no definitive evidence linking human breast, or other estrogen-dependent tumors, to the use of spironolactone exists, and data to support safety of spironolactone in this regard are increasing [<a href="#rid115">115-117</a>]. For example, a retrospective analysis of 29,146 patients with a history of breast cancer (including 746 who were prescribed spironolactone) did not find an association between spironolactone treatment and increased breast cancer recurrence [<a href="#rid115">115</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fetal effects</strong> – Feminization of the male fetus is a potential risk for patients who become pregnant while taking <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>. Animal studies have demonstrated feminization of male offspring of rodents treated with high doses of spironolactone [<a href="#rid118">118</a>]. While there are case reports of feminization of the human male fetus, there are also reports of women taking oral spironolactone and delivering male fetuses without this adverse effect [<a href="#rid119">119,120</a>].</p><p></p><p class="bulletIndent1">We advise patients to avoid pregnancy during <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> therapy and to discontinue treatment immediately if pregnancy occurs. Coadministration of spironolactone with an oral contraceptive is often a favorable option for contraception because of the beneficial effects on acne and prevention of menstrual irregularity secondary to spironolactone. (See <a class="local">'Oral contraceptives'</a> above.)</p><p></p><p class="headingAnchor" id="H2022500988"><span class="h2">Other agents</span><span class="headingEndMark"> — </span>Additional therapies with antiandrogenic properties may improve acne but are not typically used for this indication due to specific indications or concern for adverse effects:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic glucocorticoids</strong> – Systemic glucocorticoid therapy is used to suppress adrenal androgen production in patients with hyperandrogenism secondary to congenital adrenal hyperplasia [<a href="#rid121">121</a>]. Treatment with systemic glucocorticoids provides cortisol replacement, thereby reducing the excessive secretion of corticotropin-releasing hormone (CRH) and corticotropin (ACTH) that contributes to excessive adrenal androgen production, acne, and other associated clinical manifestations  (<a class="graphic graphic_figure graphicRef81907" href="/z/d/graphic/81907.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/z/d/html/136.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Flutamide</strong> – <a class="drug drug_general" data-topicid="8471" href="/z/d/drug information/8471.html" rel="external">Flutamide</a> is an androgen receptor blocker that is not typically used for the treatment of acne because of the potential for flutamide-induced fatal hepatitis [<a href="#rid122">122,123</a>].</p><p></p><p class="headingAnchor" id="H1500696741"><span class="h1">APPROACH TO SEVERE VARIANTS</span><span class="headingEndMark"> — </span>Patients with acne fulminans or acne conglobata may benefit from distinct approaches to therapy.</p><p class="headingAnchor" id="H3396992129"><span class="h2">Acne fulminans</span><span class="headingEndMark"> — </span>Acne fulminans is a rare, severe form of acne vulgaris characterized by the abrupt development of large, inflammatory nodules and friable plaques with erosions, ulcers, and hemorrhagic crusts, with or without associated systemic findings. Acne fulminans may occur following the initiation of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> or spontaneously. (See  <a class="medical medical_review" href="/z/d/html/39.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris", section on 'Acne fulminans'</a>.)</p><p>Oral glucocorticoids (typically, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 0.5 to 1 mg/kg per day) and oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> are the mainstays of treatment for acne fulminans. There is a paucity of high-quality data to guide the approach to treatment. Recommendations from a panel of clinicians with expertise in severe acne vulgaris include the following  (<a class="graphic graphic_algorithm graphicRef113850" href="/z/d/graphic/113850.html" rel="external">algorithm 3</a>) [<a href="#rid124">124</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with isotretinoin-induced acne fulminans (with or without systemic symptoms), discontinue <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> immediately and treat similarly to patients without isotretinoin-induced disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with acne fulminans with systemic symptoms, initiate oral glucocorticoid monotherapy at least four weeks prior to starting oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> to prevent a flare of the condition.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with acne fulminans without systemic symptoms, initiate oral glucocorticoid monotherapy at least two weeks prior to starting oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Start low-dose <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> (0.1 mg/kg per day) and continue with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> for at least four weeks. After this period, the dose of isotretinoin can be gradually increased, as tolerated, and the oral glucocorticoid can be slowly tapered over four to eight weeks, as tolerated. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If flares occur during treatment, extending the course of oral glucocorticoid therapy or temporary discontinuation of oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> may be required  (<a class="graphic graphic_algorithm graphicRef113850" href="/z/d/graphic/113850.html" rel="external">algorithm 3</a>).</p><p></p><p>The typical goal cumulative dose of <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> for acne vulgaris is 120 to 150 mg/kg. Greater cumulative doses may be required for patients with refractory acne fulminans [<a href="#rid124">124</a>]. (See  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris"</a>.)</p><p>Combination therapy with oral glucocorticoids and oral tetracyclines (eg, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> or <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> [100 mg twice daily] or <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> [500 to 1000 mg twice daily]) has also been used for treatment but may not be as effective as oral glucocorticoids and <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> and is not recommended as first-line treatment [<a href="#rid124">124</a>]. Other alternative treatments that have seemed beneficial in case reports include high-potency topical corticosteroids [<a href="#rid125">125</a>], <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid126">126</a>], <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> [<a href="#rid127">127,128</a>], levamisole [<a href="#rid124">124</a>], and pulsed dye laser [<a href="#rid129">129</a>]. </p><p>There is a lack of data on the effects of biologic therapies for recalcitrant acne fulminans. Based upon reports of benefit of anti-tumor necrosis factor (TNF) biologic therapy in patients with acne conglobata and SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome, it is conceivable that such treatment may be beneficial. (See <a class="local">'Acne conglobata'</a> below and  <a class="medical medical_review" href="/z/d/html/99510.html" rel="external">"SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H2890751547"><span class="h2">Acne conglobata</span><span class="headingEndMark"> — </span>Acne conglobata is a severe form of nodular acne vulgaris that may result in drainage, sinus tracts, and severe scarring. (See  <a class="medical medical_review" href="/z/d/html/39.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris", section on 'Acne conglobata'</a>.)</p><p>Oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> is the treatment of choice for acne conglobata. However, patients may experience severe flares at the start of isotretinoin therapy. Similar to acne fulminans, low initial doses of isotretinoin (0.5 mg/kg per day or less) plus systemic glucocorticoids before or during isotretinoin therapy are often required for patients with acne conglobata [<a href="#rid130">130</a>]. (See  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris", section on 'Initiation of therapy'</a>.)</p><p>Other treatments that have been used for acne conglobata include systemic antibiotics, intralesional glucocorticoids, systemic glucocorticoids, and surgical intervention [<a href="#rid130">130</a>]. Case reports have documented improvement in acne conglobata during treatment with biologic TNF-alpha inhibitors (<a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> [<a href="#rid131">131</a>], <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> [<a href="#rid132">132</a>], and combination therapy with <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> and <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> [<a href="#rid133">133</a>]). However, further study is necessary before treatment with these agents can be recommended.</p><p class="headingAnchor" id="H4176123351"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114928.html" rel="external">"Society guideline links: Acne vulgaris"</a>.)</p><p class="headingAnchor" id="H1935092510"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate to severe acne vulgaris</strong> – Acne vulgaris is a common disorder that may cause discomfort, disfigurement, and psychosocial distress. There is no universally accepted method of assessing acne severity. Moderate to severe acne may be considered acne that is  (<a class="graphic graphic_picture graphicRef98493 graphicRef98494 graphicRef57925 graphicRef55681" href="/z/d/graphic/98493.html" rel="external">picture 1A-D</a>) (see <a class="local">'Definition of moderate to severe acne'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Visually prominent, consisting of many comedones, inflamed papules, or pustules</p><p class="bulletIndent2"><span class="glyph">•</span>Associated with large papules or nodules (&gt;5 mm diameter)</p><p class="bulletIndent2"><span class="glyph">•</span>Involving multiple body areas</p><p class="bulletIndent2"><span class="glyph">•</span>Associated with scarring</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of systemic therapy</strong> – Systemic therapy is commonly utilized for moderate to severe acne vulgaris in an attempt to optimize and simplify treatment. The major systemic therapies for acne vulgaris include oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, oral antibiotics, and oral hormonal therapies (oral contraceptives and <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>)  (<a class="graphic graphic_algorithm graphicRef130260" href="/z/d/graphic/130260.html" rel="external">algorithm 2</a>). (See <a class="local">'General approach'</a> above.)</p><p></p><p class="bulletIndent1">Certain features of moderate to severe acne vulgaris prompt strong consideration of systemic therapy. For patients with nodular lesions, extensive skin involvement, or acne scarring, we suggest early initiation of systemic therapy, rather than delaying systemic treatment until failure of topical therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'When to use systemic therapy'</a> above.)</p><p></p><p class="bulletIndent1">Patients with a high psychologic burden from acne vulgaris are also candidates for early initiation of systemic therapy. (See <a class="local">'When to use systemic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of other therapies</strong> – Topical therapy often plays an important role in the treatment of moderate to severe acne vulgaris in patients who are receiving systemic therapy, with the exception of oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, which is typically given as monotherapy. In addition, patients who decline or cannot receive systemic therapy are managed with topical and/or procedural therapies. (See <a class="local">'Use of topical therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selection and use of systemic therapy</strong> – Selection of an appropriate systemic therapy for acne vulgaris involves consideration of the clinical manifestations (lesion type and severity), patient characteristics (eg, sex, age, pregnancy status, risk factors for adverse effects), and patient preference  (<a class="graphic graphic_algorithm graphicRef130260" href="/z/d/graphic/130260.html" rel="external">algorithm 2</a>) (see <a class="local">'Selection of a systemic therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oral </strong><strong>isotretinoin</strong> – For patients who present with severe, extensive, nodular acne vulgaris, we suggest oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, rather than other treatments, as initial therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Oral isotretinoin is considered the only medication that can permanently alter the natural course of acne vulgaris and has the potential to induce long-term remissions off therapy. Patients with acne fulminans or acne conglobata often require coadministration of a systemic glucocorticoid to reduce risk for isotretinoin-induced acne flares  (<a class="graphic graphic_algorithm graphicRef113850" href="/z/d/graphic/113850.html" rel="external">algorithm 3</a>). (See <a class="local">'Oral isotretinoin'</a> above and <a class="local">'Approach to severe variants'</a> above and  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris"</a>.)</p><p></p><p class="bulletIndent2">Oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> is also appropriate for less severe acne vulgaris that has failed to respond to other therapies or is associated with scarring or acne-induced psychologic distress. (See <a class="local">'Oral isotretinoin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antibiotics</strong> – Conscientious use of oral antibiotics is advised as part of antimicrobial stewardship. For patients who are treated with oral antibiotics for acne vulgaris, we suggest use of <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> antibiotics, rather than other antibiotic therapies (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Examples include <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, and <a class="drug drug_general" data-topicid="119255" href="/z/d/drug information/119255.html" rel="external">sarecycline</a>. Other antibiotics are reserved for patients who cannot tolerate or fail to respond to tetracyclines. (See <a class="local">'Oral antibiotics'</a> above.)</p><p></p><p class="bulletIndent2">Treatment course for oral antibiotics should be limited to three to four months whenever feasible. In addition, antibiotics should be used in conjunction with topical <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">benzoyl peroxide</a>. Combining oral antibiotic therapy with the use of benzoyl peroxide decreases the development of antibiotic resistance. (See <a class="local">'Appropriate use'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hormonal therapies</strong> – Postmenarchal females are candidates for hormonal therapies, including oral contraceptives and <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>. Selection between these therapies is based upon consideration of patient preference and risk for treatment-related adverse effects. For patients of childbearing potential who also desire a contraception method and lack contraindications to oral contraceptive treatment, we suggest an oral contraceptive, rather than spironolactone, as the initial hormonal therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Oral hormonal therapies'</a> above.)</p><p></p><p class="bulletIndent2">Hyperkalemia is a potential adverse effect of <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> therapy; however, the risk for hyperkalemia is low in young, healthy women given spironolactone for acne. We suggest <strong>not </strong>performing routine monitoring of serum potassium levels in healthy women under the age of 45 years receiving spironolactone for acne vulgaris (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically monitor serum potassium levels in women over the age of 45, women taking medications that may increase risk for hyperkalemia, and women with multiple medical problems, cardiac disease, or renal disease. (See <a class="local">'Spironolactone'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016; 74:945.</a></li><li><a class="nounderline abstract_t">Thiboutot DM, Shalita AR, Yamauchi PS, et al. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol 2006; 142:597.</a></li><li><a class="nounderline abstract_t">Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: a status report. Dermatol Clin 2009; 27:1.</a></li><li><a class="nounderline abstract_t">Webster GF, Graber EM. Antibiotic treatment for acne vulgaris. Semin Cutan Med Surg 2008; 27:183.</a></li><li><a class="nounderline abstract_t">Cunliffe WJ, Holland KT, Bojar R, Levy SF. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002; 24:1117.</a></li><li><a class="nounderline abstract_t">Eady EA, Farmery MR, Ross JI, et al. Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and -resistant skin bacteria from acne patients. Br J Dermatol 1994; 131:331.</a></li><li><a class="nounderline abstract_t">Thiboutot D, Zaenglein A, Weiss J, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol 2008; 59:792.</a></li><li><a class="nounderline abstract_t">Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 1997; 37:590.</a></li><li><a class="nounderline abstract_t">Peck GL, Olsen TG, Butkus D, et al. Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. J Am Acad Dermatol 1982; 6:735.</a></li><li><a class="nounderline abstract_t">Peck GL, Olsen TG, Yoder FW, et al. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N Engl J Med 1979; 300:329.</a></li><li><a class="nounderline abstract_t">Jones H, Blanc D, Cunliffe WJ. 13-cis retinoic acid and acne. Lancet 1980; 2:1048.</a></li><li><a class="nounderline abstract_t">Farrell LN, Strauss JS, Stranieri AM. The treatment of severe cystic acne with 13-cis-retinoic acid. Evaluation of sebum production and the clinical response in a multiple-dose trial. J Am Acad Dermatol 1980; 3:602.</a></li><li><a class="nounderline abstract_t">Lehucher-Ceyrac D, Weber-Buisset MJ. Isotretinoin and acne in practice: a prospective analysis of 188 cases over 9 years. Dermatology 1993; 186:123.</a></li><li><a class="nounderline abstract_t">McElwee NE, Schumacher MC, Johnson SC, et al. An observational study of isotretinoin recipients treated for acne in a health maintenance organization. Arch Dermatol 1991; 127:341.</a></li><li><a class="nounderline abstract_t">Jones DH, King K, Miller AJ, Cunliffe WJ. A dose-response study of I3-cis-retinoic acid in acne vulgaris. Br J Dermatol 1983; 108:333.</a></li><li><a class="nounderline abstract_t">Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 1984; 10:490.</a></li><li><a class="nounderline abstract_t">Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris--10 years later: a safe and successful treatment. Br J Dermatol 1993; 129:292.</a></li><li><a class="nounderline abstract_t">Blasiak RC, Stamey CR, Burkhart CN, et al. High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA Dermatol 2013; 149:1392.</a></li><li><a class="nounderline abstract_t">Amichai B, Shemer A, Grunwald MH. Low-dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol 2006; 54:644.</a></li><li><a class="nounderline abstract_t">Lee JW, Yoo KH, Park KY, et al. Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. Br J Dermatol 2011; 164:1369.</a></li><li><a class="nounderline abstract_t">Cyrulnik AA, Viola KV, Gewirtzman AJ, Cohen SR. High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life. Int J Dermatol 2012; 51:1123.</a></li><li><a class="nounderline abstract_t">Costa CS, Bagatin E, Martimbianco ALC, et al. Oral isotretinoin for acne. Cochrane Database Syst Rev 2018; 11:CD009435.</a></li><li><a class="nounderline abstract_t">Webster GF, Toso SM, Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. Arch Dermatol 1994; 130:748.</a></li><li><a class="nounderline abstract_t">Del Rosso JQ, Gallo RL, Thiboutot D, et al. Status Report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society. Part 2: Perspectives on Antibiotic Use and the Microbiome and Review of Microbiologic Effects of Selected Specific Therapeutic Agents Commonly Used by Dermatologists. J Clin Aesthet Dermatol 2016; 9:11.</a></li><li><a class="nounderline abstract_t">Del Rosso JQ, Webster GF, Rosen T, et al. Status Report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 1: Antibiotic Prescribing Patterns, Sources of Antibiotic Exposure, Antibiotic Consumption and Emergence of Antibiotic Resistance, Impact of Alterations in Antibiotic Prescribing, and Clinical Sequelae of Antibiotic Use. J Clin Aesthet Dermatol 2016; 9:18.</a></li><li><a class="nounderline abstract_t">Adler BL, Kornmehl H, Armstrong AW. Antibiotic Resistance in Acne Treatment. JAMA Dermatol 2017; 153:810.</a></li><li><a class="nounderline abstract_t">Cooper AJ. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Aust 1998; 169:259.</a></li><li><a class="nounderline abstract_t">Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br J Dermatol 2001; 144:339.</a></li><li><a class="nounderline abstract_t">Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant? : implications of resistance for acne patients and prescribers. Am J Clin Dermatol 2003; 4:813.</a></li><li><a class="nounderline abstract_t">Levy RM, Huang EY, Roling D, et al. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol 2003; 139:467.</a></li><li><a class="nounderline abstract_t">Margolis DJ, Fanelli M, Kupperman E, et al. Association of pharyngitis with oral antibiotic use for the treatment of acne: a cross-sectional and prospective cohort study. Arch Dermatol 2012; 148:326.</a></li><li><a class="nounderline abstract_t">Margolis DJ, Bowe WP, Hoffstad O, Berlin JA. Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch Dermatol 2005; 141:1132.</a></li><li><a class="nounderline abstract_t">Nguyen LH, Örtqvist AK, Cao Y, et al. Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden. Lancet Gastroenterol Hepatol 2020; 5:986.</a></li><li><a class="nounderline abstract_t">Margolis DJ, Fanelli M, Hoffstad O, Lewis JD. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol 2010; 105:2610.</a></li><li><a class="nounderline abstract_t">Armstrong AW, Hekmatjah J, Kircik LH. Oral Tetracyclines and Acne: A Systematic Review for Dermatologists. J Drugs Dermatol 2020; 19:s6.</a></li><li><a class="nounderline abstract_t">Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis 2007; 79:9.</a></li><li><a class="nounderline abstract_t">Ochsendorf F. Systemic antibiotic therapy of acne vulgaris. J Dtsch Dermatol Ges 2006; 4:828.</a></li><li><a class="nounderline abstract_t">Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003; 139:459.</a></li><li><a class="nounderline abstract_t">Toossi P, Farshchian M, Malekzad F, et al. Subantimicrobial-dose doxycycline in the treatment of moderate facial acne. J Drugs Dermatol 2008; 7:1149.</a></li><li><a class="nounderline abstract_t">Moore A, Ling M, Bucko A, et al. Efficacy and Safety of Subantimicrobial Dose, Modified-Release Doxycycline 40 mg Versus Doxycycline 100 mg Versus Placebo for the treatment of Inflammatory Lesions in Moderate and Severe Acne: A Randomized, Double-Blinded, Controlled Study. J Drugs Dermatol 2015; 14:581.</a></li><li><a class="nounderline abstract_t">Plewig G, Petrozzi JW, Berendes U. Double-blind study of doxycycline in acne vulgaris. Arch Dermatol 1970; 101:435.</a></li><li><a class="nounderline abstract_t">McManus P, Iheanacho I. Don't use minocycline as first line oral antibiotic in acne. BMJ 2007; 334:154.</a></li><li><a class="nounderline abstract_t">Purdy S, de Berker D. Acne. BMJ 2006; 333:949.</a></li><li><a class="nounderline abstract_t">Garner SE, Eady A, Bennett C, et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 2012; :CD002086.</a></li><li><a class="nounderline abstract_t">Extended-release minocycline (Solodyn) for acne. Med Lett Drugs Ther 2006; 48:95.</a></li><li><a class="nounderline abstract_t">Stewart DM, Torok HM, Weiss JS, et al. Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris. Cutis 2006; 78:11.</a></li><li><a class="nounderline abstract_t">Fleischer AB Jr, Dinehart S, Stough D, et al. Safety and efficacy of a new extended-release formulation of minocycline. Cutis 2006; 78:21.</a></li><li><a class="nounderline abstract_t">Eady EA, Cove JH, Holland KT, Cunliffe WJ. Superior antibacterial action and reduced incidence of bacterial resistance in minocycline compared to tetracycline-treated acne patients. Br J Dermatol 1990; 122:233.</a></li><li><a class="nounderline abstract_t">Eady EA, Jones CE, Gardner KJ, et al. Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline, but sensitive to minocycline. Br J Dermatol 1993; 128:556.</a></li><li><a class="nounderline abstract_t">Gough A, Chapman S, Wagstaff K, et al. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 1996; 312:169.</a></li><li><a class="nounderline abstract_t">Elkayam O, Levartovsky D, Brautbar C, et al. Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena. Am J Med 1998; 105:484.</a></li><li><a class="nounderline abstract_t">Sturkenboom MC, Meier CR, Jick H, Stricker BH. Minocycline and lupuslike syndrome in acne patients. Arch Intern Med 1999; 159:493.</a></li><li><a class="nounderline abstract_t">Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: an overview. Semin Arthritis Rheum 1999; 28:392.</a></li><li class="breakAll">www.accessdata.fda.gov/drugsatfda_docs/label/2018/209521s000lbl.pdf (Accessed on October 05, 2018).</li><li><a class="nounderline abstract_t">Moore A, Green LJ, Bruce S, et al. Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials. J Drugs Dermatol 2018; 17:987.</a></li><li><a class="nounderline abstract_t">Zhanel G, Critchley I, Lin LY, Alvandi N. Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Gratton D, Raymond GP, Guertin-Larochelle S, et al. Topical clindamycin versus systemic tetracycline in the treatment of acne. Results of a multiclinic trial. J Am Acad Dermatol 1982; 7:50.</a></li><li><a class="nounderline abstract_t">Gammon WR, Meyer C, Lantis S, et al. Comparative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris. A double-blind study. J Am Acad Dermatol 1986; 14:183.</a></li><li><a class="nounderline abstract_t">Kim JE, Park AY, Lee SY, et al. Comparison of the Efficacy of Azithromycin Versus Doxycycline in Acne Vulgaris: A Meta-Analysis of Randomized Controlled Trials. Ann Dermatol 2018; 30:417.</a></li><li><a class="nounderline abstract_t">Rafiei R, Yaghoobi R. Azithromycin versus tetracycline in the treatment of acne vulgaris. J Dermatolog Treat 2006; 17:217.</a></li><li><a class="nounderline abstract_t">Kus S, Yucelten D, Aytug A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol 2005; 30:215.</a></li><li><a class="nounderline abstract_t">Antonio JR, Pegas JR, Cestari TF, Do Nascimento LV. Azithromycin pulses in the treatment of inflammatory and pustular acne: efficacy, tolerability and safety. J Dermatolog Treat 2008; 19:210.</a></li><li><a class="nounderline abstract_t">Kardeh S, Saki N, Jowkar F, et al. Efficacy of Azithromycin in Treatment of Acne Vulgaris: A Mini Review. World J Plast Surg 2019; 8:127.</a></li><li><a class="nounderline abstract_t">Eady EA, Cove JH, Holland KT, Cunliffe WJ. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989; 121:51.</a></li><li><a class="nounderline abstract_t">Fenner JA, Wiss K, Levin NA. Oral cephalexin for acne vulgaris: clinical experience with 93 patients. Pediatr Dermatol 2008; 25:179.</a></li><li><a class="nounderline abstract_t">George R, Clarke S, Thiboutot D. Hormonal therapy for acne. Semin Cutan Med Surg 2008; 27:188.</a></li><li><a class="nounderline abstract_t">Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet 2012; 379:361.</a></li><li><a class="nounderline abstract_t">Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; :CD004425.</a></li><li><a class="nounderline abstract_t">Roberts EE, Nowsheen S, Davis DMR, et al. Use of spironolactone to treat acne in adolescent females. Pediatr Dermatol 2021; 38:72.</a></li><li><a class="nounderline abstract_t">Koulianos GT. Treatment of acne with oral contraceptives: criteria for pill selection. Cutis 2000; 66:281.</a></li><li><a class="nounderline abstract_t">Thorneycroft IH. Update on androgenicity. Am J Obstet Gynecol 1999; 180:288.</a></li><li><a class="nounderline abstract_t">Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first line therapy? facts and controversies. Clin Dermatol 2010; 28:17.</a></li><li><a class="nounderline abstract_t">Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49:S1.</a></li><li><a class="nounderline abstract_t">Tan J. Hormonal treatment of acne: review of current best evidence. J Cutan Med Surg 2004; 8 Suppl 4:11.</a></li><li><a class="nounderline abstract_t">Huber J, Walch K. Treating acne with oral contraceptives: use of lower doses. Contraception 2006; 73:23.</a></li><li><a class="nounderline abstract_t">Palombo-Kinne E, Schellschmidt I, Schumacher U, Gräser T. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate. Contraception 2009; 79:282.</a></li><li><a class="nounderline abstract_t">Koltun W, Maloney JM, Marr J, Kunz M. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 μg plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis. Eur J Obstet Gynecol Reprod Biol 2011; 155:171.</a></li><li><a class="nounderline abstract_t">Maloney JM, Dietze P Jr, Watson D, et al. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol 2008; 112:773.</a></li><li><a class="nounderline abstract_t">Gruber DM, Sator MO, Joura EA, et al. Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial. Arch Dermatol 1998; 134:459.</a></li><li><a class="nounderline abstract_t">Thorneycroft lH, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 2004; 74:123.</a></li><li><a class="nounderline abstract_t">Carlborg L. Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Results of a multicenter study. Acta Obstet Gynecol Scand Suppl 1986; 134:29.</a></li><li><a class="nounderline abstract_t">Lachnit-Fixson U, Kaufmann J. [Therapy of androgenization symptoms: double blind study of an antiandrogen preparation (SH B 209 AB) against neogynon (author's transl)]. Med Klin 1977; 72:1922.</a></li><li><a class="nounderline abstract_t">Worret I, Arp W, Zahradnik HP, et al. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 2001; 203:38.</a></li><li><a class="nounderline abstract_t">Monk BE, Almeyda JA, Caldwell IW, et al. Efficacy of low-dose cyproterone acetate compared with minocycline in the treatment of acne vulgaris. Clin Exp Dermatol 1987; 12:319.</a></li><li><a class="nounderline abstract_t">Greenwood R, Brummitt L, Burke B, Cunliffe WJ. Acne: double blind clinical and laboratory trial of tetracycline, oestrogen-cyproterone acetate, and combined treatment. Br Med J (Clin Res Ed) 1985; 291:1231.</a></li><li><a class="nounderline abstract_t">Koo EB, Petersen TD, Kimball AB. Meta-analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgaris. J Am Acad Dermatol 2014; 71:450.</a></li><li><a class="nounderline abstract_t">Sehovic N, Smith KP. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products. Ann Pharmacother 2010; 44:898.</a></li><li class="breakAll">http://whqlibdoc.who.int/hq/2008/WHO_RHR_08.19_eng.pdf (Accessed on April 21, 2011).</li><li class="breakAll">www.accessdata.fda.gov/drugsatfda_docs/label/2006/021676s000lbl.pdf (Accessed on May 13, 2009).</li><li><a class="nounderline abstract_t">Dickinson BD, Altman RD, Nielsen NH, et al. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 2001; 98:853.</a></li><li><a class="nounderline abstract_t">Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004; 18:737.</a></li><li><a class="nounderline abstract_t">Zouboulis CC, Akamatsu H, Stephanek K, Orfanos CE. Androgens affect the activity of human sebocytes in culture in a manner dependent on the localization of the sebaceous glands and their effect is antagonized by spironolactone. Skin Pharmacol 1994; 7:33.</a></li><li><a class="nounderline abstract_t">Thiboutot D, Chen W. Update and future of hormonal therapy in acne. Dermatology 2003; 206:57.</a></li><li><a class="nounderline abstract_t">Brown J, Farquhar C, Lee O, et al. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev 2009; :CD000194.</a></li><li><a class="nounderline abstract_t">Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol 1984; 111:209.</a></li><li><a class="nounderline abstract_t">Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol 1985; 112:124.</a></li><li><a class="nounderline abstract_t">Muhlemann MF, Carter GD, Cream JJ, Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol 1986; 115:227.</a></li><li><a class="nounderline abstract_t">Yemisci A, Gorgulu A, Piskin S. Effects and side-effects of spironolactone therapy in women with acne. J Eur Acad Dermatol Venereol 2005; 19:163.</a></li><li><a class="nounderline abstract_t">Saint-Jean M, Ballanger F, Nguyen JM, et al. Importance of spironolactone in the treatment of acne in adult women. J Eur Acad Dermatol Venereol 2011; 25:1480.</a></li><li><a class="nounderline abstract_t">Grandhi R, Alikhan A. Spironolactone for the Treatment of Acne: A 4-Year Retrospective Study. Dermatology 2017; 233:141.</a></li><li><a class="nounderline abstract_t">Roberts EE, Nowsheen S, Davis MDP, et al. Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007-2017. J Eur Acad Dermatol Venereol 2020; 34:2106.</a></li><li><a class="nounderline abstract_t">Park JH, Bienenfeld A, Orlow SJ, Nagler AR. The Use of Hormonal Antiandrogen Therapy in Female Patients with Acne: A 10-Year Retrospective Study. Am J Clin Dermatol 2018; 19:449.</a></li><li><a class="nounderline abstract_t">Charny JW, Choi JK, James WD. Spironolactone for the treatment of acne in women, a retrospective study of 110 patients. Int J Womens Dermatol 2017; 3:111.</a></li><li><a class="nounderline abstract_t">Patiyasikunt M, Chancheewa B, Asawanonda P, et al. Efficacy and tolerability of low-dose spironolactone and topical benzoyl peroxide in adult female acne: A randomized, double-blind, placebo-controlled trial. J Dermatol 2020; 47:1411.</a></li><li><a class="nounderline abstract_t">Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol 2004; 22:419.</a></li><li><a class="nounderline abstract_t">Sato K, Matsumoto D, Iizuka F, et al. Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians. Aesthetic Plast Surg 2006; 30:689.</a></li><li><a class="nounderline abstract_t">Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol 2000; 43:498.</a></li><li><a class="nounderline abstract_t">Lubbos HG, Hasinski S, Rose LI, Pollock J. Adverse effects of spironolactone therapy in women with acne. Arch Dermatol 1998; 134:1162.</a></li><li class="breakAll">Sawaya ME. Anitiandrogens and androgen inhibitors. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE (Ed), Elsevier, 2007. p.417.</li><li class="breakAll">http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm121173.htm (Accessed on April 21, 2011).</li><li><a class="nounderline abstract_t">Loughlin J, Seeger JD, Eng PM, et al. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives. Contraception 2008; 78:377.</a></li><li><a class="nounderline abstract_t">Plovanich M, Weng QY, Mostaghimi A. Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne. JAMA Dermatol 2015; 151:941.</a></li><li><a class="nounderline abstract_t">Thiede RM, Rastogi S, Nardone B, et al. Hyperkalemia in women with acne exposed to oral spironolactone: A retrospective study from the RADAR (Research on Adverse Drug Events and Reports) program. Int J Womens Dermatol 2019; 5:155.</a></li><li><a class="nounderline abstract_t">Krunic A, Ciurea A, Scheman A. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone. J Am Acad Dermatol 2008; 58:60.</a></li><li><a class="nounderline abstract_t">Wei C, Bovonratwet P, Gu A, et al. Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis. J Am Acad Dermatol 2020; 83:1021.</a></li><li><a class="nounderline abstract_t">Biggar RJ, Andersen EW, Wohlfahrt J, Melbye M. Spironolactone use and the risk of breast and gynecologic cancers. Cancer Epidemiol 2013; 37:870.</a></li><li><a class="nounderline abstract_t">Mackenzie IS, Morant SV, Wei L, et al. Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. Br J Clin Pharmacol 2017; 83:653.</a></li><li><a class="nounderline abstract_t">Hecker A, Hasan SH, Neumann F. Disturbances in sexual differentiation of rat foetuses following spironolactone treatment. Acta Endocrinol (Copenh) 1980; 95:540.</a></li><li><a class="nounderline abstract_t">Rigó J Jr, Gláz E, Papp Z. Low or high doses of spironolactone for treatment of maternal Bartter's syndrome. Am J Obstet Gynecol 1996; 174:297.</a></li><li><a class="nounderline abstract_t">Groves TD, Corenblum B. Spironolactone therapy during human pregnancy. Am J Obstet Gynecol 1995; 172:1655.</a></li><li><a class="nounderline abstract_t">Bachelot A, Chakthoura Z, Rouxel A, et al. Classical forms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults. Horm Res 2008; 69:203.</a></li><li><a class="nounderline abstract_t">Wysowski DK, Freiman JP, Tourtelot JB, Horton ML 3rd. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 1993; 118:860.</a></li><li><a class="nounderline abstract_t">García Cortés M, Andrade RJ, Lucena MI, et al. Flutamide-induced hepatotoxicity: report of a case series. Rev Esp Enferm Dig 2001; 93:423.</a></li><li><a class="nounderline abstract_t">Greywal T, Zaenglein AL, Baldwin HE, et al. Evidence-based recommendations for the management of acne fulminans and its variants. J Am Acad Dermatol 2017; 77:109.</a></li><li><a class="nounderline abstract_t">Miller RA, Ross JB, Martin J. Multiple granulation tissue lesions occurring in isotretinoin treatment of acne vulgaris--successful response to topical corticosteroid therapy. J Am Acad Dermatol 1985; 12:888.</a></li><li><a class="nounderline abstract_t">Giavedoni P, Mascaró-Galy JM, Aguilera P, Estrach-Panella T. Acne fulminans successfully treated with cyclosporine and isotretinoin. J Am Acad Dermatol 2014; 70:e38.</a></li><li><a class="nounderline abstract_t">Lages RB, Bona SH, Silva FV, et al. Acne fulminans successfully treated with prednisone and dapsone. An Bras Dermatol 2012; 87:612.</a></li><li><a class="nounderline abstract_t">Tan BB, Lear JT, Smith AG. Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone. Clin Exp Dermatol 1997; 22:26.</a></li><li><a class="nounderline abstract_t">Friedlander SF. Effective treatment of acne fulminans-associated granulation tissue with the pulsed dye laser. Pediatr Dermatol 1998; 15:396.</a></li><li class="breakAll">Zaenglein AK, Graber EM, Thiboutot DM, et al. Acne vulgaris and acneiform eruptions. In: Dermatology in General Medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al (Eds), McGraw Hill, 2008. p.690.</li><li><a class="nounderline abstract_t">Campione E, Mazzotta AM, Bianchi L, Chimenti S. Severe acne successfully treated with etanercept. Acta Derm Venereol 2006; 86:256.</a></li><li><a class="nounderline abstract_t">Sand FL, Thomsen SF. Adalimumab for the treatment of refractory acne conglobata. JAMA Dermatol 2013; 149:1306.</a></li><li><a class="nounderline abstract_t">Shirakawa M, Uramoto K, Harada FA. Treatment of acne conglobata with infliximab. J Am Acad Dermatol 2006; 55:344.</a></li></ol></div><div id="topicVersionRevision">Topic 129467 Version 10.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26897386" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Guidelines of care for the management of acne vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16702497" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18984363" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: a status report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18786496" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antibiotic treatment for acne vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12182256" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7918006" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and -resistant skin bacteria from acne patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18805603" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9344199" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6461677" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/153472" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6107678" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : 13-cis retinoic acid and acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6451637" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The treatment of severe cystic acne with 13-cis-retinoic acid. Evaluation of sebum production and the clinical response in a multiple-dose trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8428040" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Isotretinoin and acne in practice: a prospective analysis of 188 cases over 9 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1825596" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : An observational study of isotretinoin recipients treated for acne in a health maintenance organization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6219690" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A dose-response study of I3-cis-retinoic acid in acne vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6233335" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Isotretinoin therapy for acne: results of a multicenter dose-response study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8286227" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Isotretinoin for acne vulgaris--10 years later: a safe and successful treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24173086" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16546586" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Low-dose isotretinoin in the treatment of acne vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21114478" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22909370" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30484286" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Oral isotretinoin for acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8002645" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Status Report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society. Part 2: Perspectives on Antibiotic Use and the Microbiome and Review of Microbiologic Effects of Selected Specific Therapeutic Agents Commonly Used by Dermatologists</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27462384" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Status Report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 1: Antibiotic Prescribing Patterns, Sources of Antibiotic Exposure, Antibiotic Consumption and Emergence of Antibiotic Resistance, Impact of Alterations in Antibiotic Prescribing, and Clinical Sequelae of Antibiotic Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28636689" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Antibiotic Resistance in Acne Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9762064" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Systematic review of Propionibacterium acnes resistance to systemic antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11251569" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14640775" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Is antibiotic resistance in cutaneous propionibacteria clinically relevant? : implications of resistance for acne patients and prescribers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12707094" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effect of antibiotics on the oropharyngeal flora in patients with acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22105812" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Association of pharyngitis with oral antibiotic use for the treatment of acne: a cross-sectional and prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16172310" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Antibiotic treatment of acne may be associated with upper respiratory tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32818437" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20700115" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33196746" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Oral Tetracyclines and Acne: A Systematic Review for Dermatologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17649854" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17010172" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Systemic antibiotic therapy of acne vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12707093" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19137768" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Subantimicrobial-dose doxycycline in the treatment of moderate facial acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26091383" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy and Safety of Subantimicrobial Dose, Modified-Release Doxycycline 40 mg Versus Doxycycline 100 mg Versus Placebo for the treatment of Inflammatory Lesions in Moderate and Severe Acne: A Randomized, Double-Blinded, Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4245454" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Double-blind study of doxycycline in acne vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17235098" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Don't use minocycline as first line oral antibiotic in acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17082546" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22895927" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Minocycline for acne vulgaris: efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17106435" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Extended-release minocycline (Solodyn) for acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17436825" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17436826" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Safety and efficacy of a new extended-release formulation of minocycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2138493" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Superior antibacterial action and reduced incidence of bacterial resistance in minocycline compared to tetracycline-treated acne patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8504049" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline, but sensitive to minocycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8563540" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9870833" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10074958" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Minocycline and lupuslike syndrome in acne patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10406406" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Minocycline-induced autoimmune syndromes: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10406406" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Minocycline-induced autoimmune syndromes: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30235387" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30397052" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6213682" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Topical clindamycin versus systemic tetracycline in the treatment of acne. Results of a multiclinic trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2936772" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Comparative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris. A double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30065581" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Comparison of the Efficacy of Azithromycin Versus Doxycycline in Acne Vulgaris: A Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16971315" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Azithromycin versus tetracycline in the treatment of acne vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15807672" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18608737" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Azithromycin pulses in the treatment of inflammatory and pustular acne: efficacy, tolerability and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31309049" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Efficacy of Azithromycin in Treatment of Acne Vulgaris: A Mini Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2527056" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18429774" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Oral cephalexin for acne vulgaris: clinical experience with 93 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18786497" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Hormonal therapy for acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880356" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Acne vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22696343" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Combined oral contraceptive pills for treatment of acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33009838" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Use of spironolactone to treat acne in adolescent females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11109151" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Treatment of acne with oral contraceptives: criteria for pill selection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9988832" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Update on androgenicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20082945" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Hormonal therapy for acne: why not as first line therapy? facts and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12833004" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Management of acne: a report from a Global Alliance to Improve Outcomes in Acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15778821" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Hormonal treatment of acne: review of current best evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16371290" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Treating acne with oral contraceptives: use of lower doses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19272497" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21288628" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20μg plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18827119" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9554298" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15379365" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2949481" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Results of a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/144842" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : [Therapy of androgenization symptoms: double blind study of an antiandrogen preparation (SH B 209 AB) against neogynon (author's transl)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11549798" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2965628" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Efficacy of low-dose cyproterone acetate compared with minocycline in the treatment of acne vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2933119" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Acne: double blind clinical and laboratory trial of tetracycline, oestrogen-cyproterone acetate, and combined treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24880665" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Meta-analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20371756" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Risk of venous thromboembolism with drospirenone in combined oral contraceptive products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20371756" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Risk of venous thromboembolism with drospirenone in combined oral contraceptive products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20371756" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Risk of venous thromboembolism with drospirenone in combined oral contraceptive products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11704183" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Drug interactions between oral contraceptives and antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15380144" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Hirsutism and acne in polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8003320" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Androgens affect the activity of human sebocytes in culture in a manner dependent on the localization of the sebaceous glands and their effect is antagonized by spironolactone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12566806" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Update and future of hormonal therapy in acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19370553" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6235834" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Oral spironolactone improves acne vulgaris and reduces sebum excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3155956" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2943311" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Oral spironolactone: an effective treatment for acne vulgaris in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15752283" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Effects and side-effects of spironolactone therapy in women with acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21114688" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Importance of spironolactone in the treatment of acne in adult women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28472793" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Spironolactone for the Treatment of Acne: A 4-Year Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32078195" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29556985" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The Use of Hormonal Antiandrogen Therapy in Female Patients with Acne: A 10-Year Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28560306" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Spironolactone for the treatment of acne in women, a retrospective study of 110 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32857471" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Efficacy and tolerability of low-dose spironolactone and topical benzoyl peroxide in adult female acne: A randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15556729" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Acne: hormonal concepts and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17077951" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10954662" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9762041" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Adverse effects of spironolactone therapy in women with acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9762041" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Adverse effects of spironolactone therapy in women with acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9762041" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Adverse effects of spironolactone therapy in women with acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18929734" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25796182" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31360748" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Hyperkalemia in women with acne exposed to oral spironolactone: A retrospective study from the RADAR (Research on Adverse Drug Events and Reports) program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17964689" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32446820" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24189467" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Spironolactone use and the risk of breast and gynecologic cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27735065" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Spironolactone use and risk of incident cancers: a retrospective, matched cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7456979" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Disturbances in sexual differentiation of rat foetuses following spironolactone treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8572029" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Low or high doses of spironolactone for treatment of maternal Bartter's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7755100" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Spironolactone therapy during human pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18204267" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Classical forms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7683180" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Fatal and nonfatal hepatotoxicity associated with flutamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11685939" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Flutamide-induced hepatotoxicity: report of a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28619551" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Evidence-based recommendations for the management of acne fulminans and its variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3159762" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Multiple granulation tissue lesions occurring in isotretinoin treatment of acne vulgaris--successful response to topical corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24438977" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Acne fulminans successfully treated with cyclosporine and isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22892777" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Acne fulminans successfully treated with prednisone and dapsone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9330049" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9796595" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Effective treatment of acne fulminans-associated granulation tissue with the pulsed dye laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9796595" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Effective treatment of acne fulminans-associated granulation tissue with the pulsed dye laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16710590" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Severe acne successfully treated with etanercept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24048280" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Adalimumab for the treatment of refractory acne conglobata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16844527" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Treatment of acne conglobata with infliximab.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
